Poggesi I - Search Results

1

Pharmacokinetic-Pharmacodynamic Modeling of the Ponesimod Effect on Heart Rate in Patients With Multiple Sclerosis.

Valenzuela B, Poggesi I, Luyckx N, Vaclavkova A, Pérez-Ruixo JJ. Valenzuela B, et al. Among authors: poggesi i. Clin Pharmacol Ther. 2023 Mar;113(3):692-703. doi: 10.1002/cpt.2827. Epub 2023 Jan 30. Clin Pharmacol Ther. 2023. PMID: 36524329

2

An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis.

Gisleskog PO, Valenzuela B, Scherz T, Burcklen M, Pérez-Ruixo JJ, Poggesi I. Gisleskog PO, et al. Among authors: poggesi i. Clin Pharmacokinet. 2021 Sep;60(9):1227-1237. doi: 10.1007/s40262-021-01020-2. Epub 2021 Apr 29. Clin Pharmacokinet. 2021. PMID: 33914286 Clinical Trial.

3

An exposure-response analysis of ponesimod clinical efficacy in a randomized phase III study in patients with relapsing multiple sclerosis.

Valenzuela B, Olsson Gisleskog P, Poggesi I, Sidorenko T, Burcklen M, Kracker H, Pérez-Ruixo JJ. Valenzuela B, et al. Among authors: poggesi i. CPT Pharmacometrics Syst Pharmacol. 2022 Oct;11(10):1294-1304. doi: 10.1002/psp4.12778. Epub 2022 Sep 1. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 36047474 Free PMC article. Clinical Trial.

4

Population pharmacokinetics of trabectedin in adolescent patients with cancer.

Poggesi I, Valenzuela B, Ouellet D, Gonzalez M, Hillewaert V, Baruchel S, Fox E, Perez-Ruixo JJ. Poggesi I, et al. Cancer Chemother Pharmacol. 2019 Oct;84(4):707-717. doi: 10.1007/s00280-019-03899-y. Epub 2019 Jul 8. Cancer Chemother Pharmacol. 2019. PMID: 31286189

5

Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects.

Axelsen LN, Poggesi I, Rasschaert F, Perez Ruixo JJ, Bruderer S. Axelsen LN, et al. Among authors: poggesi i. Br J Clin Pharmacol. 2021 Jan;87(1):119-128. doi: 10.1111/bcp.14365. Epub 2020 Jun 5. Br J Clin Pharmacol. 2021. PMID: 32415684 Free PMC article.

6

Effect of Ponesimod Exposure on Total Lymphocyte Dynamics in Patients with Multiple Sclerosis.

Valenzuela B, Pérez-Ruixo JJ, Leirens Q, Ouwerkerk-Mahadevan S, Poggesi I. Valenzuela B, et al. Among authors: poggesi i. Clin Pharmacokinet. 2021 Sep;60(9):1239-1250. doi: 10.1007/s40262-021-01019-9. Epub 2021 Apr 29. Clin Pharmacokinet. 2021. PMID: 33914285

7

Erdafitinib's effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer.

Dosne AG, Valade E, Stuyckens K, De Porre P, Avadhani A, O'Hagan A, Li LY, Ouellet D, Faelens R, Leirens Q, Poggesi I, Perez Ruixo JJ. Dosne AG, et al. Among authors: poggesi i. CPT Pharmacometrics Syst Pharmacol. 2022 May;11(5):569-580. doi: 10.1002/psp4.12727. Epub 2021 Nov 22. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 34755484 Free PMC article.

8

A Population Pharmacokinetic Model of Macitentan and Its Active Metabolite Aprocitentan in Healthy Volunteers and Patients with Pulmonary Arterial Hypertension.

Bartolucci R, Dosne AG, Csonka D, Pérez-Ruixo JJ, Magni P, Poggesi I. Bartolucci R, et al. Among authors: poggesi i. Clin Pharmacokinet. 2021 Dec;60(12):1605-1619. doi: 10.1007/s40262-021-01049-3. Epub 2021 Jun 23. Clin Pharmacokinet. 2021. PMID: 34159557

9

A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib.

Tosca EM, Terranova N, Stuyckens K, Dosne AG, Perera T, Vialard J, King P, Verhulst T, Perez-Ruixo JJ, Magni P, Poggesi I. Tosca EM, et al. Among authors: poggesi i. Cancer Chemother Pharmacol. 2022 Jan;89(1):117-128. doi: 10.1007/s00280-021-04370-7. Epub 2021 Nov 17. Cancer Chemother Pharmacol. 2022. PMID: 34786600

10

Population Pharmacokinetic Analysis of Decitabine in Pediatric Patients With Acute Myeloid Leukemia.

Zhou W, Parasrampuria DA, Nemat S, Nakahara S, Poggesi I, Massarella J, Zhang L, Appiani C. Zhou W, et al. Among authors: poggesi i. J Clin Pharmacol. 2019 May;59(5):668-676. doi: 10.1002/jcph.1357. Epub 2018 Dec 11. J Clin Pharmacol. 2019. PMID: 30536675

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

98 results

Search Page